SUTRO BIOPHARMA INC.

Sutro Biopharma Reports First Quarter 2024 Financial Results, Business Highlights and Select Anticipated Milestones

13 مايو 2024 13:30:00 بحسب Nasdaq GlobeNewswire

Sutro Biopharma Announces Initiation of Randomized Portion (Part 2) of REFRαME-O1 Trial

30 أبريل 2024 05:00:01 بحسب Nasdaq GlobeNewswire

Sutro Biopharma Announces Pricing of $75 Million Underwritten Offering

02 أبريل 2024 03:18:56 بحسب Nasdaq GlobeNewswire

Sutro Biopharma Reports Full Year 2023 Financial Results, Business Highlights and Select Anticipated Milestones

25 مارس 2024 13:30:00 بحسب Nasdaq GlobeNewswire

Sutro Biopharma to Participate in Upcoming Investor Conferences

06 فبراير 2024 13:05:00 بحسب Nasdaq GlobeNewswire

Sutro Biopharma Highlights Potential Multi-Cancer Opportunity for Luvelta, a FolRα-targeting ADC

04 يناير 2024 13:05:00 بحسب Nasdaq GlobeNewswire

Sutro Biopharma to Host Investor Webcast Highlighting Potential Multi-Cancer Opportunity for Luvelta, a FolRα-targeted ADC, on January 4, 2024

14 ديسمبر 2023 13:05:00 بحسب Nasdaq GlobeNewswire

Sutro Biopharma Announces New Positive Data from the Compassionate Use of Luveltamab Tazevibulin (luvelta) in Pediatric Patients with Relapsed/Refractory CBF/GLIS Presented at ASH 2023

11 ديسمبر 2023 13:05:00 بحسب Nasdaq GlobeNewswire

Sutro Biopharma to Participate in the JMP Securities Hematology and Oncology Summit

04 ديسمبر 2023 13:05:00 بحسب Nasdaq GlobeNewswire

Sutro Biopharma Promotes Jane Chung to President and Chief Operating Officer

21 نوفمبر 2023 13:05:00 بحسب Nasdaq GlobeNewswire

Sutro Biopharma Reports Third Quarter 2023 Financial Results, Business Highlights and Select Anticipated Milestones

13 نوفمبر 2023 13:30:00 بحسب Nasdaq GlobeNewswire

Sutro Biopharma Announces Presentation of Data for Luveltamab Tazevibulin (luvelta) from the Phase 1 Dose-Expansion Study in Endometrial Cancers at ESMO 2023

22 أكتوبر 2023 01:25:00 بحسب Nasdaq GlobeNewswire

Sutro Demonstrates Meaningful ADC Innovation with Five Presentations and One Poster at the 14th Annual World ADC Conference

16 أكتوبر 2023 13:05:00 بحسب Nasdaq GlobeNewswire

Sutro Biopharma Appoints Dr. Hans-Peter Gerber as Chief Scientific Officer

19 سبتمبر 2023 05:00:00 بحسب Nasdaq GlobeNewswire

Sutro Biopharma to Participate in Upcoming Investor Conferences

30 أغسطس 2023 05:00:00 بحسب Nasdaq GlobeNewswire

Sutro Biopharma Reports Second Quarter 2023 Financial Results, Business Highlights and Select Anticipated Milestones

10 أغسطس 2023 13:30:00 بحسب Nasdaq GlobeNewswire

Sutro Biopharma and Blackstone Announce Royalty Financing Collaboration

26 يونيو 2023 05:00:00 بحسب Nasdaq GlobeNewswire

Sutro Biopharma Announces Oral Presentation at ASCO 2023 Featuring Data for Luveltamab Tazevibulin from the Phase 1 Dose-Expansion Study in Ovarian Cancer and the Initiation of the Phase 2/3 Pivotal Study REFRaME-O1

03 يونيو 2023 13:00:00 بحسب Nasdaq GlobeNewswire

Sutro Biopharma to Participate in the Jefferies Healthcare Conference

31 مايو 2023 05:00:00 بحسب Nasdaq GlobeNewswire

Sutro Biopharma Reports First Quarter 2023 Financial Results, Business Highlights and Select Anticipated Milestones

15 مايو 2023 05:00:01 بحسب Nasdaq GlobeNewswire